Affiliation:
1. Department of Medicine, Division of Endocrinology, Duke University Medical Center Durham, North Carolina 27706
Abstract
The mechanism(s) by which chronic glybenclamide therapy lowers the plasma glucose and improves diabetic control was studied in patients with adult-onset diabetes mellitus. Two months of therapy with glybenclamide resulted in a striking improvement in oral glucose tolerance associated with an increase in both plasma insulin and the insulin/glucose ratio. This improvement in glucose tolerance persisted through six months of therapy. However, the plasma insulin response to glucose and the insulin/glucose ratio decreased significantly toward pretreatment levels. During the study period there were no alterations in growth hormone secretion, thyroid function, adrenal cortical function or adrenal medullary function. The data suggest that glybenclamide, a new sulfonylurea drug, may improve diabetic control and improve glucose tolerance through a mechanism other than increased insulin secretion.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
108 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献